ARUP's Laboratory Test Directory

Thanatophoric Dysplasia, Types I and II (FGFR3) 13 Mutations : 0051506
[ image for: Patient History For Molecular Genetics]
Patient History For Molecular Genetics
  


Mnemonic: TD PAN

Methodology: Polymerase Chain Reaction/Fragment Analysis
Performed: Sun-Sat
Reported: 3-7 days
Specimen Required: Collect:  One 3 mL lavender (EDTA), pink (K2EDTA) or yellow (ACD solution A or B).

Transport:  3 mL whole blood at 2-8°C. (Min: 1 mL)

Pediatric Collection/Transport:  1 mL whole blood at 2-8°C.

Stability:  Ambient: 3 days; Refrigerated: 1 week; Frozen: Unacceptable
Interpretive Data: Background information for Thanatophoric Dysplasia, Types I and II (FGFR3) 13 Mutations
Characteristics:
Micromelia, macrocephaly, short ribs and a narrow thorax; TD I has bowed femurs and TD II has straight femurs and a cloverleaf skull; death usually occurs from respiratory insufficiency within hours or days of birth.
Incidence:
1 in 6,000 to 50,000 births.
Inheritance:
Autosomal dominant; arising from a de novo mutation.
Cause:
Fibroblast growth factor receptor 3 (FGFR3) gene mutations.
Mutations tested:
c.742C>T (R248C), c.746C>G (S249C), c.1108G>T (G370C), c.1111A>T (S371C), c.1118A>G (Y373C), c.2419T>G (X807G), c.2419T>A (X807R), c.2420G>T (X807L), c.2420G>C (X807S), c.2421A>T (X807C), c.2421A>C (X807C) and c.2421A>G (X807W) for TD I and c.1948A>G (K650E) for TD II.
Clinical Sensitivity and Specificity:
99 percent.
Methodology:
Polymerase chain reaction (PCR) and single nucleotide extension followed by capillary electrophoresis.
Analytic Specificity and Sensitivity
: 99 percent.
Limitations:
Mutations other than those targeted in FGFR3 will not be detected; analytic sensitivity may be compromised by rare primer site mutations.

This test is performed pursuant to an agreement with Roche Molecular Systems, Inc.





Please refer to Statement C in the Compliance Statements section in the front of the Laboratory Test Directory.
CPT Code(s): 83890 Isolation; 83900 Multiplex amplification; 83901 x2 Additional amplification; 83914 x9 Extension; 83909 Capillary electrophoresis; 83912 Interpretation and report - Additional CPT code modifiers may be required for procedures performed to test for oncologic or inherited disorders.
 
 

 

 

 
All ARUP Sites:        www.aruplab.com     ·     www.arupconsult.com     ·     www.arup.utah.edu     ·     www.childx.org     ·     www.utahblood.org